Copper-peptide research comparison

GHK-Cu vs AHK-Cu: peptide identity and evidence limits

An educational comparison of GHK-Cu and AHK-Cu: how their amino-acid sequences differ, what laboratory and isolated-follicle studies measured, and why formulation matters when reading topical claims.

Educational guideUpdated August 29, 2026

How to compare the evidence accurately

Read the full ingredient name: glycyl-histidyl-lysine copper for GHK-Cu versus alanyl-histidyl-lysine copper for AHK-Cu. Do not assume every “copper peptide” serum contains either one.

Identify the model: cells, isolated follicles, wound models, or treated people provide different levels of evidence.

Match the claim to the exact peptide, concentration, vehicle, body site, outcome, and study duration.

Separate a mechanistic change—such as cell proliferation or follicle elongation—from demonstrated cosmetic or clinical benefit in people.

Look for replicated controlled studies of a finished formulation before generalizing from a raw ingredient or laboratory preparation.

Direct answer

GHK-Cu and AHK-Cu are different copper-binding tripeptide complexes, not interchangeable names for one proven hair or skin treatment. GHK-Cu contains glycyl-histidyl-lysine, while AHK-Cu contains alanyl-histidyl-lysine. GHK-Cu appears in a broader tissue-remodeling and cosmetic-research literature; the frequently cited AHK-Cu hair study tested isolated human follicles and cultured dermal papilla cells, not a finished topical in a randomized scalp trial. Peptide12 does not offer, prescribe, compound, sell, or facilitate access to AHK-Cu or injectable copper-peptide products. This page is an educational review, not a dosing or treatment guide.

Ingredient identity

One amino-acid difference does not make GHK-Cu and AHK-Cu the same product

GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine; AHK-Cu is the copper complex of L-alanyl-L-histidyl-L-lysine. Their first amino acid differs—glycine in GHK and alanine in AHK—so product labels, evidence, concentration, vehicle, and intended use should be evaluated separately. GHK-Cu is discussed in a wider skin, tissue-remodeling, oxidative-stress, and cosmetic literature. AHK-Cu is especially visible in hair-peptide marketing, but marketing shorthand should not erase the narrower evidence base.

“Copper peptide,” “copper tripeptide,” GHK-Cu, and AHK-Cu are not reliable synonyms unless the ingredient label identifies the actual compound.
Evidence for one copper peptide is not evidence for a different peptide, research powder, injectable material, or multi-ingredient cosmetic blend.
Neither ingredient should be described as an FDA-approved finished drug for androgenetic alopecia, alopecia areata, wounds, scars, wrinkles, or skin disease.

Evidence limits

The key AHK-Cu hair paper was ex vivo and in vitro—not a clinical regrowth trial

A 2007 study evaluated AHK-Cu in isolated human hair follicles outside the body and in cultured dermal papilla cells. It reported follicle elongation and dermal-papilla-cell proliferation under those laboratory conditions. That is useful mechanistic evidence, but it does not establish real-world benefit, dosing, long-term safety, or comparative effectiveness for a finished scalp product. Reviews discuss GHK-Cu across tissue-remodeling and cosmetic contexts, yet those findings also should not be transferred automatically to every concentration, vehicle, body site, or seller.

There is no cited head-to-head randomized trial showing that GHK-Cu or AHK-Cu is “better” for hair density, skin firmness, wrinkles, or recovery.
An isolated human follicle is human-derived tissue, but it is not the same as a treated person in a controlled scalp study.
Ask whether a claim comes from the exact peptide, route, formula, outcome, and population—or from a different compound, laboratory model, wound context, or broad review.

Translating the research

Skin, scalp, and follicle studies are not interchangeable

A peptide can behave differently in a cell culture, an isolated follicle, intact skin, and a finished topical formulation. The often-cited AHK-Cu experiment observed isolated follicles and cultured dermal papilla cells under controlled laboratory conditions. GHK-Cu reviews draw from a wider mix of tissue, wound, skin, and biochemical research. Those settings can help explain a mechanism, but they do not create a head-to-head ranking for hair density, wrinkle reduction, scalp symptoms, or a diagnosed condition.

Follicle elongation outside the body is a laboratory outcome, not a measurement of visible hair regrowth in a treated population.
Findings from wound or tissue-remodeling models should not be relabeled as proof of wrinkle, scar, or hair-loss benefit.
A useful human study would define the finished formula, comparison group, population, outcome measurement, duration, and adverse-event collection in advance.

Formulation science

A raw ingredient result does not predict every finished topical

Vehicle, concentration, stability, packaging, skin penetration, application site, and the other ingredients in a formula can all change exposure and tolerability. That is why a laboratory result for a dissolved peptide cannot establish the performance of every cream, serum, foam, powder, or blend using a similar name. A well-designed topical study evaluates the finished formulation rather than borrowing a conclusion from the ingredient alone.

A concentration number has limited meaning without identity testing, stability information, delivery vehicle, and a relevant outcome study.
Results should not be transferred between topical, injectable, microneedled, and laboratory routes.
Guaranteed regrowth, “collagen on demand,” wound healing, scar erasure, and age reversal go beyond what the cited evidence establishes.

Research-reading checklist

A research-literacy checklist for copper-peptide claims

Use these questions to assess the quality and limits of public research. This page does not recommend or facilitate use of an unapproved substance.

✓

Does the source identify glycyl-histidyl-lysine copper, alanyl-histidyl-lysine copper, or a different copper complex?

✓

Was the work performed in cells, isolated follicles, animals, human skin, or a controlled trial in people?

✓

Does the claim match the exact peptide, concentration, vehicle, route, body site, outcome, and duration studied?

✓

Is isolated-follicle elongation being incorrectly presented as proven visible hair regrowth?

✓

Was the finished topical studied, or is the conclusion borrowed from a raw ingredient or different formulation?

✓

How many participants or samples were included, what was the comparison group, and was the result replicated?

✓

Were clinically meaningful outcomes and adverse events measured, or only molecular and microscopic changes?

✓

Does the source clearly state the limitations rather than claiming established human benefit, calling one peptide “stronger,” or guaranteeing an outcome?

✓

Does the page avoid injectable instructions, dosing, access guidance, and treatment recommendations for AHK-Cu?

FAQs

Short evidence answers

What is the main difference between GHK-Cu and AHK-Cu?

GHK-Cu contains the tripeptide glycyl-histidyl-lysine bound to copper, while AHK-Cu contains alanyl-histidyl-lysine bound to copper. The first amino acid differs, and the compounds have different research histories. Do not assume evidence for one proves the other product works.

Is AHK-Cu proven to regrow hair in people?

The frequently cited 2007 AHK-Cu paper studied isolated human hair follicles outside the body and cultured dermal papilla cells. It was not a randomized scalp trial of a finished product, so it cannot establish clinical regrowth, long-term safety, or superiority over established hair-loss care.

Is GHK-Cu better than AHK-Cu for skin?

There is no head-to-head clinical evidence establishing a universal winner. GHK-Cu has a broader tissue-remodeling and cosmetic literature, while AHK-Cu is more narrowly discussed in hair-peptide research. Breadth of literature alone does not prove that one finished topical will produce a better outcome.

Has combining GHK-Cu and AHK-Cu been shown to improve outcomes?

The sources cited here do not establish that combining them improves hair or skin outcomes. Without suitable controlled evidence, a combination claim should be treated as an untested hypothesis rather than a demonstrated benefit.

Are GHK-Cu and AHK-Cu FDA approved for hair loss or wrinkles?

No. They should not be described as FDA-approved finished drugs for hair loss, wrinkles, wounds, scars, or skin disease. Cosmetic and compounded products also need accurate identity, route, sourcing, labeling, and evidence boundaries.

When should hair loss be evaluated before trying a peptide serum?

Seek evaluation for sudden or patchy loss, scalp pain, scaling, pus, scarring, eyebrow or body-hair changes, rapid weight change, pregnancy-related changes, new medications, or possible thyroid, iron, autoimmune, or nutritional causes. A topical peptide should not delay diagnosis.

What online copper-peptide sellers should I avoid?

Avoid sellers offering research-use powders or vials for human use, injectable or microneedling protocols, hidden ingredient identity, no-prescription compounded products, fake before-and-afters, and guaranteed hair-regrowth, wound-healing, collagen, scar, or age-reversal outcomes.

Sources and related reading

Primary regulatory sources and complete study reports provide the clearest context for research-stage substances.

PubMed: AHK-Cu and human hair follicles ex vivo and dermal papilla cells in vitro PubMed: The human tripeptide GHK and tissue remodeling PubMed Central: GHK-Cu, oxidative stress, and aging review PubMed Central: 2026 overview of short peptides for hair loss FDA: Cosmetics under U.S. law FDA: Compounding and the FDA—Questions and Answers Peptide12: GHK-Cu topical foam guide Peptide12: GHK-Cu vs copper peptide serum Peptide12: GHK-Cu vs minoxidil Peptide12: GHK-Cu for hair-loss questions Peptide12: GHK-Cu side effects and safety Peptide12: Skin and hair peptide therapy